Key result
Tei index detects subclinical anthracycline cardiotoxicity earlier and outperforms conventional LVEF across multiple studies.
Why the study?
Anthracycline cardiotoxicity commonly manifests as LVSD, and because diastolic dysfunction likely precedes systolic impairment, the Tei index may offer additional benefit in detecting subclinical LVSD.
Does the Tei index improve the detection of subclinical cardiotoxicity in patients receiving anthracycline chemotherapy compared to LVEF?
Systematic Review (n=800)
Yes
Does the Tei index improve the detection of subclinical cardiotoxicity in patients receiving anthracycline chemotherapy compared to LVEF?
The Tei index may be a useful indicator for assessing subclinical anthracycline-related cardiotoxicity, but current evidence is inconsistent and insufficient for routine use.
Answers are grounded in this paper and cite their sources.
Supports Tei index for subclinical anthracycline cardiotoxicity detection; extends prior studies but leaves open need for prospective validation.
BACKGROUND: Anthracycline agents are known to be effective in treating tumors and hematological malignancies. Although these agents improve survival, their use is associated with cardiotoxic effects, which most commonly manifests as left ventricular systolic dysfunction (LVSD). As such, guidelines recommend the periodic assessment of left ventricular ejection fraction (LVEF). However, as diastolic dysfunction likely proceeds systolic impairment in this setting, the role of Tei index may offer additional benefit in detecting subclinical LVSD. METHODS: We conducted a systematic review to investigate the evidence for the use of Tei index in assessing subclinical cardiotoxicity in patients receiving anticancer agents. A search of Medline and EMBASE was performed and relevant studies were reviewed and narratively synthesized. RESULTS: A total of 13 studies were included with a total of 800 patients (mean age range 46-62 years, percentage of male participants ranged from 0-86.9%). An increase in Tei index was observed in 11 studies, which suggested a decline in cardiac function following chemotherapy. Out of these, six studies indicated that the Tei index is a useful parameter in predicting cardiotoxic LVSD. Furthermore, five studies indicated Tei index to be superior to LVEF in detecting subclinical cardiotoxicity. CONCLUSIONS: Though there are some studies that suggest that Tei index may be a useful indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are inconsistent and so more studies are needed before the evaluation of Tei index is performed routinely in patients receiving chemotherapy.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (2021) conducted a systematic review in Anthracycline chemotherapy-induced subclinical cardiotoxicity in cancer patients (n=800). Tei index (myocardial performance index) assessment in patients receiving anthracycline chemotherapy vs. Left ventricular ejection fraction (LVEF) or baseline pre-chemotherapy values was evaluated on Subclinical cardiotoxicity / left ventricular systolic dysfunction (LVSD) detection. Tei index increased after anthracycline chemotherapy in 11 of 13 studies and predicted subclinical cardiotoxicity in 6 studies, outperforming LVEF in 5 studies.
Synapse has enriched 10 related papers. Consider them for comparative context: